5 “Strong Buy” Biotech Stocks to Buy Now

Biotech stocks often present intriguing, and potentially very lucrative, investment opportunities. Share prices can explode on positive trial results or key regulatory approvals.

However, buyers beware: These rewards can disappear just as quickly if critical data disappoints. This is especially the case for biotechnology companies with few or no marketable drugs (and thus they are generating low or even no revenues), especially if their drugs still are in the early stages of development. To minimize this risk, it's best to search for stocks with a high degree of confidence from Wall Street's top analysts.

Five compelling biotech stocks stand out as intriguing investing opportunities right now.

We used TipRanks' to filter for the best-rated biotechnology stocks over the past few weeks, regardless of market capitalization. All five stocks share a bullish "Strong Buy" analyst consensus rating. And while all five picks have soared over

You're reading a preview, sign up to read more.

More from Kiplinger

Kiplinger6 min read
10 Financial Commandments for Your 30s
Your finances might have felt like a plague in your 20s, but thou shalt thrive throughout your 30s and beyond. Our list of Financial Commandments for your 20s helped you find your financial footing and establish a solid foundation. Now that you're ol
Kiplinger2 min readPolitics
Medicare Premiums Snafu Affects 250,000 Social Security Recipients
It seems like the simple, hassle-free way to pay your Medicare premiums: Have them withheld from your Social Security benefits. But now, about 250,000 seniors who opted to have their Medicare premiums taken out of their Social Security checks are get
Kiplinger4 min read
Is 4% Withdrawal Rate Still a Good Retirement Rule of Thumb?
The general guideline of withdrawing no more than 4% of your portfolio each year during retirement has come under fire as of late. This guideline was the result of a study conducted almost 30-years ago by William Bengen, at a time when it was believ